The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment free remission (TFR) and overall response rate (ORR) results in patients with relapsed/refractory Waldenstrom’s macroglobulinemia (WM) treated with CLR 131.
 
Sikander Ailawadhi
Honoraria - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Janssen (Inst)
Consulting or Advisory Role - Beigene; Celgene; GlaxoSmithKline; Oncopeptides; Sanofi; Takeda
Research Funding - Amgen (Inst); BMS (Inst); Cellectar (Inst); Janssen Biotech (Inst); MedImmune (Inst); Pharmacyclics (Inst); Phosplatin Therapeutics (Inst); Xencor (Inst)
 
Asher Alban Akmal Chanan-Khan
Stock and Other Ownership Interests - Matthew & Asher Inc.; NanoDev Therapeutics
Honoraria - BeiGene
Research Funding - Ascentage Pharma
Patents, Royalties, Other Intellectual Property - Patent on PSMB9 biomarker
 
Jennifer Layton Peterson
No Relationships to Disclose
 
Jarrod Longcor
Employment - Cellectar
Stock and Other Ownership Interests - Cellectar
 
Katherine Oliver
Employment - Cellectar
Stock and Other Ownership Interests - Cellectar
 
Matthew Francis Brown
Employment - Cellectar; Merck Sharp & Dohme
Stock and Other Ownership Interests - Cellectar; Merck Sharp & Dohme
 
John Friend
Employment - Cellect Biotechnology; Druggablity Technologies
Stock and Other Ownership Interests - Cellectar; Druggablity Technologies
 
Damian Jonathan Green
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Celgene; GlaxoSmithKline; Janssen Oncology; Juno Therapeutics; Legend Biotech; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Cellectar (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Merck (Inst); Sanofi (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Intellectual property on pending patents related to the combination of a small molecule with BCMA targeted CAR-T cell therapy. Royalty sharing agreement in place.